---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-092578"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:31:31.744507+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics FY 2025 net loss $88.6M; top-line divesiran data on-track for Q3 2026

## Summary
- Net loss widened to $88.6M ($0.63/share) from $45.3M ($0.33/share) in FY 2024.
- Collaboration revenue dropped to $0.6M from $43.3M; R&D spend flat at $67.8M.
- Cash and investments $85.1M as of Dec 31, 2025; key Phase 2 SANRECO topline due Q3 2026.
- AstraZeneca will not develop SLN312 beyond Phase 1; Silence regains global rights.
- CEO search underway after former CEO departure in Dec 2025; Iain Ross interim.

## SEC filing metadata
- accession: 0001193125-26-092578
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/0001193125-26-092578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/sln-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-092578
- JSON: https://secwatch.observer/filing/0001193125-26-092578.json
- Plain text: https://secwatch.observer/filing/0001193125-26-092578.txt

## Key facts
- Earnings Releases
  Silence Therapeutics plc reported the fourth quarter and full year ended December 31, 2025 results: revenue $0.6 million, net income $88.6 million, EPS $0.63 basic and diluted net loss per share.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Revenue: $0.6 million
  - Net income: $88.6 million
  - EPS: $0.63 basic and diluted net loss per share
  - Result: reported results
  source text: Full Year 2025 Financial Results • Cash Position: Cash, cash equivalents, and short-term investments were $85.1 million as of December 31, 2025. This includes cash and cash equivalents of $11.3 million and short-term investments of $73.8 million. • Collaboration Revenue: Collaboration revenue was $0.6 million for the year ended December 31, 2025, compared to $43.3 million for the year ended December 31, 2024. The decrease for 2025 was primarily due to revenue associated with the Hansoh collaboration that concluded in 2024 and a $17.4 million decrease in revenue related to the AstraZeneca collaboration. • R&D Expenses: Research and development (R&D) expenses were $67.8 million for the year ended December 31, 2025, compared to $67.9 million for the year ended December 31, 2024. • G&A Expenses: General and administrative (G&A) expenses were $22.3 million for the year ended December 31, 2025, compared to $26.9 million for the year ended December 31, 2024. The decrease for 2025 was primaril
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/0001193125-26-092578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.